There are 2789 resources available
Q&A and live discussion
Presenter: Jana Pelouchova
Session: How can technology & data support the cancer patient journey?
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Marianne Pavel
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Eleni Efstathiou
Session: Presidential Symposium 2 – Discussion session I: Genitourinary tumours, prostate
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Florian Lordick
Session: Presidential Symposium 2 – Discussion session II: Gastrointestinal tumours
Resources:
Slides
Webcast
177Lu-dotatate
Presenter: Eric Baudin
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Hepatic arterial embolization
Presenter: Jonathan Strosberg
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Marianne Pavel
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
Q&A
Presenter: Marianne Pavel
Session: What is the optimal 2nd line treatment for metastatic somatostatin-receptor positive, liver-dominant midgut NET?
Resources:
Slides
Webcast
579MO - CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Discussion LBA50, LBA51 & 1194MO
Presenter: David Gandara
Session: Mini oral session - NSCLC, metastatic
Resources:
Slides
Webcast